Answer
It is unknown whether pembrolizumab passes into human milk; risk to newborns/infants cannot be excluded because antibodies can enter milk, so a decision is needed whether to discontinue breast-feeding or pembrolizumab, considering the benefits of breast-feeding for the child and treatment for the woman.
Sources for this answer
- KEYTRUDA 25 mg/mL concentrate for solution for infusionMerck Sharp & Dohme (UK) Limited · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 67Document updated
Sources checked